Ipratropium vs Tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Ipratropium
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT02172287 · Phase 3 · completed
This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).
Reported efficacy
Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)
Result source: NCT02172287
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ipratropium | Tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not posted · NCT02177344 | 0.9 vs 1.3−0.4 vs placeboNCT016639871 other result
|
| Trough FEV1, change | —Not posted · NCT02177344 | 0.1 vs 0.1vs ABNCT0279667742 other results
|
| SGRQ total, change | —Not posted · NCT02177344 | -4.1 vs -2.0−2.1 vs placeboNCT00496470 |
| TDI focal score | —Not posted · NCT02177344 | —Not posted · NCT02172287 |
Moderate or severe exacerbations, annualised rate
- Ipratropium
- —Not posted · NCT02177344
- Tiotropium bromide
- 0.9 vs 1.3−0.4 vs placeboNCT01663987
1 other result
- 0.9 vs 1.3 NCT01662986
Trough FEV1, change
- Ipratropium
- —Not posted · NCT02177344
- Tiotropium bromide
- 0.1 vs 0.1vs ABNCT02796677
42 other results
- 0.2 vs -0.1 NCT01663987
- 0.2 vs 0.1 NCT01662986
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00359788
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.2 vs 0.0 NCT01663987
- 0.2 vs 0.0 NCT01662986
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.0 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs -0.0 NCT00359788
SGRQ total, change
- Ipratropium
- —Not posted · NCT02177344
- Tiotropium bromide
- -4.1 vs -2.0−2.1 vs placeboNCT00496470
TDI focal score
- Ipratropium
- —Not posted · NCT02177344
- Tiotropium bromide
- —Not posted · NCT02172287
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ipratropium: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ipratropium: 0 of 4 rows · Tiotropium bromide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tiotropium bromide |
|---|---|
| Dropout rate | 10.3%50/250 µg BIDa NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 15%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 33.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT00523991 · Phase 4 · registry result, not featured evidence 7.9% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 13.3% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 0%18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 23.2%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23.4%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 13.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 16.1%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 6.3%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.4%50/250 µg BIDa NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 10.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT00523991 · Phase 4 · registry result, not featured evidence 2.4% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 10.6%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 11.1%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 10.5%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 3.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.2%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.1%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —50/250 µg BIDa NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results5.9%50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence 8.8%50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination 10.7%18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 37.5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 25.6%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence 0%50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence 3.8%50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 4.2% NCT00523991 · Phase 4 · registry result, not featured evidence 3% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 0% NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 32.9%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.9%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.8%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 0%150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 0%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence 2%5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 50/250 µg BIDa nasopharyngitis 18.4% dysphonia 13.2% bronchitis 5.1% NCT01762800 · Phase 4 · registry result, not featured evidence show 27 more results50/250 µg BID + 18 µg QD nasopharyngitis 20.6% bronchitis 10.3% dysphonia 8.8% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18 µg QD + 50/250 µg BID nasopharyngitis 26.7% dysphonia 8% bronchitis 6.7% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18μg chronic obstructive pulmonary disease 37.5% (placebo 43.6%) bronchitis 7.5% (placebo 5.1%) insomnia 5% (placebo 5.1%) NCT01663987 · Phase 4 · registry result, not featured evidence 18 μg chronic obstructive pulmonary disease 25.6% (placebo 15.4%) contusion 7.7% (placebo 0%) oedema peripheral 7.7% (placebo 0%) NCT01662986 · Phase 4 · registry result, not featured evidence 50/250 µg BID dysphonia 5.9% constipation 2% dry mouth 2% NCT01751113 · Phase 4 · registry result, not featured evidence 50/250 µg BID + 18 µg QD dysphonia 9.6% nasopharyngitis 5.8% arthralgia 3.8% NCT01751113 · Phase 4 · registry result, not featured evidence · combination nasophayngitis 6.7% (placebo 5%) chronic obstructive pulmonary disease 4.6% (placebo 9.6%) NCT00523991 · Phase 4 · registry result, not featured evidence chronic obstructive pulmonary disease 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 32.9% NCT01126437 · Phase 3 · registry result, not featured evidence 18 mcg chronic obstructive pulmonary disease 33.9% NCT01126437 · Phase 3 · registry result, not featured evidence 2.5 mcg chronic obstructive pulmonary disease 33.8% NCT01126437 · Phase 3 · registry result, not featured evidence 10 μg cough 3.3% (placebo 0%) headache 3.3% (placebo 3%) urinary tract infection 3.3% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 40 μg dry mouth 12.9% (placebo 0%) dizziness 3.2% (placebo 6.1%) back pain 0% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 20 μg back pain 6.3% (placebo 3%) headache 6.3% (placebo 3%) cough 3.1% (placebo 0%) NCT03118765 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 9.3% (placebo 4.1%) dyspnoea 2% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 18 mcg nasopharyngitis 4.8% (placebo 4.1%) dyspnoea 2.1% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 2.5 mcg dyspnoea 1.4% (placebo 9.5%) nasopharyngitis 1.4% (placebo 4.1%) NCT01222533 · Phase 2 · registry result, not featured evidence 1.25 mcg nasopharyngitis 6.1% (placebo 4.1%) dyspnoea 3.4% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tiotropium bromide
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 116 further endpoints in the CSV export.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Ipratropium
Marketed by Boehringer Ingelheim
NCT06074185 · Phase 2 · completed
The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.
No aligned efficacy figure on record for this race.
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT00772538 · Phase 3 · completed
The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.
Next expected readout: January 2027 · NCT06679465 (registry estimate)
Reported efficacy
Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)
Result source: NCT00772538
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ipratropium | Tiotropium bromide |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | 0.1 vs -0.0+0.2 vs placeboNCT0117280840 other results
|
| ACQ-5, change | —Not reported | —Not reported |
| OCS dose reduction | —Not reported | —Not reported |
Severe exacerbations, annualised rate
- Ipratropium
- —Not reported
- Tiotropium bromide
- —Not reported
Trough FEV1, change
- Ipratropium
- —Not reported
- Tiotropium bromide
- 0.1 vs -0.0+0.2 vs placeboNCT01172808
40 other results
- 0.2 vs -0.0 NCT01172821
- 0.1 vs 0.1 NCT00772538
- 0.1 vs -0.0 NCT01172808
- 0.1 vs -0.0 NCT01172821
- 0.2 vs 0.0 NCT00776984
- 0.1 vs 0.1 NCT01340209
- 0.3 vs 0.3 NCT01634139
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.2 vs 0.1 NCT01340209
- 0.1 vs 0.1 NCT00772538
- 0.4 vs 0.3 NCT01634139
- 0.2 vs 0.1 NCT00776984
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.2 vs -0.0 NCT02573155
- 0.1 vs -0.0 NCT02573155
- 0.5 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- -0.0 vs -0.0 NCT02573155
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.3 vs 0.1 NCT01152450
- 0.4 vs 0.3 NCT01122680
- 0.3 vs 0.1 NCT01152450
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
ACQ-5, change
- Ipratropium
- —Not reported
- Tiotropium bromide
- —Not reported
OCS dose reduction
- Ipratropium
- —Not reported
- Tiotropium bromide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Ipratropium: 6 of 7 rows · Tiotropium bromide: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ipratropium | Tiotropium bromide Rows use multiple source trials |
|---|---|---|
| Asthma Symptom absolute change · score | 0.3 vs 0.4 Fluticasone HFA score @ 16wka,b,c,d,e NCT00521222 · Phase na · registry result, not featured evidence show 1 more dose-1.2 vs 0.4 Fluticasone HFA score @ 16wk NCT00521222 · Phase na · registry result, not featured evidence | -0.09 vs -0.04 LABA + 1xICS score @ 14wkb,c,d,e NCT00565266 · Phase 3 · combination · Asthma · phase 3 |
| FEV1 absolute change · L | -0.03 vs -0.12 Fluticasone HFA L @ 16wka,b,c,d,e NCT00521222 · Phase na · registry result, not featured evidence show 1 more dose-0.08 vs -0.12 Fluticasone HFA L @ 16wk NCT00521222 · Phase na · registry result, not featured evidence | 0.12 vs 0.01 LABA + 1xICS L @ 14wkb,c,d,e NCT00565266 · Phase 3 · combination · Asthma · phase 3 |
| Morning PEF Change L/Min absolute change · L/min | -15.7 vs -5.6 Fluticasone HFA L/min @ 16wka,b,c,d,f NCT00521222 · Phase na · registry result, not featured evidence show 1 more dose8.4 vs -5.6 Fluticasone HFA L/min @ 16wk NCT00521222 · Phase na · registry result, not featured evidence | 13.119 vs 8.343 placebo L/min @ 12wk2.5 mcga,b,c,d,f NCT01634152 · Phase 3 · registry result, not featured evidence · add on show 1 more dose13.086 vs 8.343 placebo L/min @ 12wk5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on |
| Dropout rate | —g NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 5.6%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination | 11%5 µg/dayh NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 4.4%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 3.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 8%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 4.4%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 7%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 7%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 8.7%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 4.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 5.1%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 3.2%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 1.9%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 9.6%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT06074185 · Phase 2 · combination show 4 more results— NCT04617015 · Phase 1 · registry result, not featured evidence —Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence —Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence — NCT00583778 · Phase na · registry result, not featured evidence · combination | 2.5%5 µg/dayh NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 —2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on —5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.5%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0.9%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.8%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 3%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 0.8%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 1.3%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.9%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%g NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination | 7.6%5 µg/dayh NCT00772538 · Phase 3 show 39 more results1.5% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.2%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 1.5%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.6%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 2.2%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 1.5%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 3.5%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 3.5%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.9%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 1.5%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 2.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 2.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 8.7%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence 0%5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence 1%2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 1.4%5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 2.2%5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 0%2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%900 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 2.9%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%200 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g upper respiratory infection 13.3% dyspnea 6.7% right foot fracture 6.7% NCT00521222 · Phase na · registry result, not featured evidence show 1 more resultdyspnea 11.8% cough 5.9% pneumonia 5.9% NCT00521222 · Phase na · registry result, not featured evidence | 5 µg/dayh asthma 34.6% (placebo 44.6%) peak expiratory flow rate decreased 20.7% (placebo 26.1%) nasopharyngitis 8% (placebo 9%) NCT00772538 · Phase 3 show 28 more resultsurgent care visit due to asthma 1% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.5 mcg asthma 36.3% (placebo 43.5%) peak expiratory flow rate decreased 23% (placebo 20.6%) nasopharyngitis 11.1% (placebo 9.9%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 34.1% (placebo 43.5%) peak expiratory flow rate decreased 21.5% (placebo 20.6%) respiratory tract infection 9.6% (placebo 12.2%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 14.7% (placebo 21.6%) peak expiratory flow rate decreased 11% (placebo 14.9%) nasopharyngitis 4.4% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 16.9% (placebo 21.6%) peak expiratory flow rate decreased 11.5% (placebo 14.9%) nasopharyngitis 4.6% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 21.6% (placebo 23.2%) nasopharyngitis 10.4% (placebo 12.3%) respiratory tract infection viral 8.8% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 5 mcg asthma 16.4% (placebo 23.2%) nasopharyngitis 14.9% (placebo 12.3%) respiratory tract infection viral 7.5% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 2.5 μg asthma 11% (placebo 10.4%) peak expiratory flow rate decreased 7.1% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 5 μg asthma 10.8% (placebo 10.4%) peak expiratory flow rate decreased 3.8% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 2.5 µg once daily nasopharyngitis 44.7% (placebo 42.1%) asthma 29.8% (placebo 36.8%) bronchitis 13.2% (placebo 7%) NCT01340209 · Phase 3 · registry result, not featured evidence 5 µg once daily nasopharyngitis 48.2% (placebo 42.1%) asthma 28.1% (placebo 36.8%) peak expiratory flow rate decreased 15.8% (placebo 21.1%) NCT01340209 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 13.7% (placebo 21.6%) peak expiratory flow rate decreased 10.7% (placebo 19%) nasopharyngitis 6.9% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 22.7% (placebo 21.6%) peak expiratory flow rate decreased 12.9% (placebo 19%) nasopharyngitis 8.3% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 17.1% (placebo 21.3%) nasopharyngitis 12.1% (placebo 10.2%) peak expiratory flow rate decreased 8.2% (placebo 11%) NCT01172821 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 19.8% (placebo 21.3%) peak expiratory flow rate decreased 9.9% (placebo 11%) nasopharyngitis 7.5% (placebo 10.2%) NCT01172821 · Phase 3 · registry result, not featured evidence 2.5 mcg asthma 15.6% (placebo 12.3%) peak expiratory flow rate decreased 5.8% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 mcg asthma 11% (placebo 12.3%) peak expiratory flow rate decreased 3.9% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 µg/day asthma 37.9% (placebo 47.9%) peak expiratory flow rate decreased 20.1% (placebo 27.4%) nasopharyngitis 14.6% (placebo 15.4%) NCT00776984 · Phase 3 · registry result, not featured evidence 2.5 µg once daily headache 7.8% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 5 µg once daily headache 5.6% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 2100 μg nasopharyngitis 40% (placebo 8.3%) bronchitis viral 20% (placebo 0%) feeling hot 20% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 16.7% (placebo 25%) nausea 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 9.7% (placebo 25%) chronic obstructive pulmonary disorder 3.2% (placebo 0%) nasopharyngitis 3.2% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 900 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) cough 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 14.7% (placebo 25%) chronic obstructive pulmonary disorder 5.9% (placebo 0%) nasopharyngitis 2.9% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 200 μg abscess oral 16.7% (placebo 0%) chest discomfort 16.7% (placebo 8.3%) chest pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 50 μg headache 50% (placebo 25%) nasopharyngitis 50% (placebo 8.3%) back pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase na.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 14 weeks versus 16 weeks.
- fAssessment timepoints differ: 12 weeks versus 16 weeks.
- gPopulation comparability has not been reviewed for these studies.
- hPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ipratropium
show 1 more result
show 1 more result
show 1 more result
Tiotropium bromide
show 30 more results
show 40 more results
show 7 more results
show 30 more results
show 28 more results
show 5 more results
show 22 more results
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 18 more results
+ 71 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · Tiotropium bromide's landscape